Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-10-18
1997-06-24
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31335
Patent
active
056418035
ABSTRACT:
Taxol dosages of about 135 mg/m.sup.2 or greater are administered via infusions of less than 6 hours duration; the method makes it possible to provide taxol infusions on an out-patient basis to patients who do not otherwise require hospitalization. In a preferred embodiment, about 135 mg/m.sup.2 of taxol in a cremaphor emulsion is infused over a 3 hour duration, following patient pretreatment with steroids, antihistamines, and H.sub.2 -receptor antagonists sufficient to prevent fatal anaphylactic-like reactions, and preferably sufficient to reduce the occurrence of severe anaphylactic-like reactions in greater than 90% of patients treated. In an alternative embodiment, between 135 mg/.sup.2 and about 175 mg/m.sup.2 of taxol is provided in a 3-hour infusion, following protreatment to minimize hypersensitivity responses. A method for rechallenging patients with taxol after episodes of acute hypersensitivity reactions is also disclosed, thus enabling patients to continue taxol therapy who would otherwise be deprived of treatment.
REFERENCES:
Longnecker et al, Proceedings of ASCO, vol. 4, Mar. 1985, C-119.
Huinink, Annales of Oncology, vol. 3, Mar. 11, 1992, p. 120, "Taxol The First Available of Taxanes, A New Class of Anticancer Drugs".
K.D. Tutsch, S. Swaminathan, D. Alberti, J. Koeller, D.C. Torney, G.T. Bryan, J.K.V. Willson, and D.L. Trump, "Phase I Clinical Trial with Pharmacokinetic Analysis of Taxol (NSC 125973) Given on a Daily X5 Schedule," Proceedings from the American Society of Clinical Oncology, vol. 4, Mar. 1985, p. 40, No. C-151.
Wiernik et al., "Taxol (T) Phase I and Pharmacokinetic Study", Proceedings of ASCO, (1986) vol. 5 (Abstract 125).
J. Koeller et al., "A Phase I Study of Taxol Given as a 6 Hour Infusion Every 21 Days", NCI-EORTC Symposium (1989) Amsterdam (Abstract 412).
S. Lagha et al., "A Phase I Study of Taxol (NSC 125973)", Proceedings of AACR, (1985) vol. 26 (Abstract 684).
Rowinsky et al., "Phase I and Pharmacodynamic Study of Taxol in Refractory Acute Leukemias", Cancer Research (1989) 49:4640-4647.
Markman et al., "Phase 1 Study of Taxol Administered by the Intraperitoneal (IP) Route: A GOG Trial", Proceedings of ASCO, (1991) vol. 10 (Abstract 601).
"Taxol IND 22850 NSC 125973", a clinical brochure, National Cancer Institute, Bethesda MD (1991).
Einzig et al., "Phase II Study of Taxol (T) in patients (Pts) with Advanced Ovarian Cancer", Proceedings of the American Association for Cancer Research (1990) vol. 31 (Abstract 1114).
Holmes et al., "Phase II Trial of Taxol, and Active Drug in the Treatment of Metastatic Breast Cancer", Journal of the National Cancer Institute 83:1797-1805 No. 24 (1989).
Einzig et al., "Phase II Trial of Taxol in Patients (Pts) with Renal Cell Carcinoma" Proceedings of AACR (1988) vol. 29 (Abstract 884).
National Cancer Institute: Clinical Brochure Taxol (NSC 125973). Bethesda Maryland Division of Cancer Treatment, NCI Sep. 1983, pp. 6-12.
Rowinsky et al., "Sequences of Taxol & Cisplatin: Phase I/Pharmacologic Study", Proceedings of ASCO (1990) vol. 9 (Abstract 290).
Einzig et al., "Phase II Pilot Study of Taxol in Patients (Pts) with Malignant Melanoma (MM)" Proceedings of ASCO (1988) vol. 7 (Abstract 963).
Longnecker et al., "High-Performance Liquid Chromatographic Assay for Taxol in Human Plasma and Urine and Pharmacokinetics in a Phase I Trial", Cancer Treatment Reports (1987) 71:53-59 No. 1.
Lipton et al., "Taxol Produces a Predominantly Sensory Neuropathy", Neurology (1989) 39:368-373.
Gynaecological Cancer Newsletter, Gynaecological Oncology Group of Victoria (1990) No. 6 pp. 1-21.
G. Sarosy et al., "Taxol Dose Intensification (D.I.) in Patients with Recurrent Ovarian Cancer", Proceedings of ASCO (1992) vol. 11 (Abstract 716).
A. Seidman et al., "Activity of Taxol with Recombinant Granulocyte Colony Stimulating Factor (FCSF) as First Chemotherapy (C) of Patients (PTS) with Metastatic Breast Cancer (MBC)", Proceedings of ASCO (1992) vol. 11 (Abstract 64).
Murphy, "A Phase II Study of Taxol (NSC 125973) in Patients (PTS) with Non-Small Cell Lung Cancer (NSCLC)", Proceedings of ASCO (1992) vol. 11 (Abstract 985).
Chang et al., "Phase II Study of Taxol in Patients with Stage IV Non-Small Cell Lung Cancer (NSCLC); The Eastern Cooperative Oncology Group (ECOG) Results", Proceedings of ASCO (1992) vol. 11 (Abstract 981).
Roth et al. "Taxol (NSC 125973) in Advanced, Hormone-Refractory Prostate Cancer: an ECOG Phase II Trial", Proceedings of ASCO (1992) vol. 11 (Abstract 598).
Spriggs et al., "Taxol Administered as a 120 Hour Infusion", Investigational New Drugs (1992) 10:275-278.
Editorial: "Taxol: Twenty Years Later, the Story Unfolds", Rowinsky et al., Journal of National Cancer Institute (1992) pp. 1178-1181.
W.W. ten Bokkel Huinink "Taxol The First Available of Taxanes, a New Class of Anticancer Drugs", The Netherlands Cancer Institute, Amsterdam, the Netherlands (Abstract 244) (1992).
Chabner, "Taxol", Principles & Practice of Oncology (1991) 5:1-10 No. 9.
Carretta Renzo Mauro
Eisenhauer Elizabeth
Rozencweig Marcel
Bristol--Myers Squibb Company
Goldberg Jerome D.
LandOfFree
Methods for administration of taxol does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for administration of taxol, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for administration of taxol will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-149534